Apthera
RXi Looks to Raise $10.9M in Public Offering; Needs More than $2M to Move Cancer Rx into Phase III
Premium
RXi also broke out its financial results for 2010 in the filing, reporting a drop in its net loss amid lower research and development spending. The company said, however, that it anticipates its expenses to increase going forward on NeuVax-related expenses.
RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one.
RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.
Mar 31, 2011